Clinical Trials
33 trialsNexCAR19
Health Institutes of Turkey
RAY-no-BAN
Turku University Hospital
Spatially Fractionated Radiation Treatment for Gynaecological Cancers
Tata Memorial Hospital
Comparison of Pathological Outcome and Recurrence Rate Between En Bloc and Conventional Transurethral Resection of Bladder Tumor
Lahore General Hospital
BIOSTOP
Helse Møre og Romsdal HF
ECAR01
Anhui Provincial Hospital
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
National Cancer Center, Japan
WoW
Vastra Gotaland Region
ACCESS-I
Instituto Nacional de Cancer, Brazil
Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9)
Turku University Hospital
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
KK Women's and Children's Hospital
The Effect of Telephone-Assisted Smoking Cessation Program in Patients Diagnosed With Non-Muscle Invasive Bladder Cancer
Bakirkoy Dr. Sadi Konuk Research and Training Hospital
AIMA-CC
ANRS, Emerging Infectious Diseases
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
Hospital General de Mexico
Survival Rates and Quality of Life According to Follow-up Period After Gastrectomy for Gastric Cancer (STOFOLUP)
National Cancer Center, Korea
Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
Shanghai Gynecologic Oncology Group
FB10
Turku University Hospital
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia
Vastra Gotaland Region
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
Sheba Medical Center
CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma
Henan Cancer Hospital
Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies
Henan Cancer Hospital
MM-POM-2018
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
Nimotuzumab for Recurrent Nasopharyngeal Carcinoma
Fujian Cancer Hospital
Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma
Henan Cancer Hospital
DAA in the Risk of Recurrence After Curative Treatment of HCC
Taipei Veterans General Hospital, Taiwan
Intravesically Heated Thermo-chemotherapy With Mitomycin-C Prior to TURBT
Sheba Medical Center
Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma
National Institute of Cancerología
Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.
National Cancer Center, Korea
Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma
Bayside Health
BNCT and IG-IMRT for Recurrent Head and Neck Cancer
Taipei Veterans General Hospital, Taiwan
FOSCAN
Ministry of Health, Malaysia
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)
National Cancer Center, Korea